Search Result

Results for "

dimerization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Androgen Receptor (2) Antibiotic (2) Apoptosis (9) Atg8/LC3 (1) Autophagy (5) Bacterial (6) Biochemical Assay Reagents (2) c-Fms (1) c-Met/HGFR (2) c-Myc (4) Calcium Channel (3) Drug Intermediate (2) EGFR (23) Endogenous Metabolite (2) ERK (3) Estrogen Receptor/ERR (2) FGFR (2) FKBP (3) Fluorescent Dye (4) Fungal (4) G-quadruplex (1) HIF/HIF Prolyl-Hydroxylase (3) HIV (7) HIV Protease (3) HuR (1) IKZF Family (1) Interleukin Related (1) IRAK (2) Isotope-Labeled Compounds (1) JNK (1) Ligands for E3 Ligase (1) MAP3K (1) Molecular Glues (1) Monocarboxylate Transporter (2) mRNA (2) MyD88 (3) NF-κB (3) NO Synthase (3) Opioid Receptor (1) p38 MAPK (1) PD-1/PD-L1 (6) PDGFR (3) Phosphatase (1) Phytohormone (2) PKA (1) PKG (1) Potassium Channel (3) PROTAC Linkers (1) PROTACs (2) Pyroptosis (1) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) Reverse Transcriptase (1) SARS-CoV (5) Somatostatin Receptor (1) STAT (7) Survivin (2) Toll-like Receptor (TLR) (3) Trk Receptor (1) VEGFR (1) Virus Protease (1) α-synuclein (2)
By Research Areas:	Cancer (70) Cardiovascular Disease (4) Endocrinology (3) Infection (15) Inflammation/Immunology (15) Metabolic Disease (2) Neurological Disease (10)
Oligonucleotides:	mRNA (2)

112

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131015

HaXS8	Biochemical Assay Reagents	Others
HaXS8 is a dimerizer that can promote a covalent and irreversible intracellular dimerization of HaloTag and SNAP-tagged proteins of interest. HaXS8 does not interfere with PI3K/mTOR signaling .

HY-136538

LQZ-7I	Survivin	Cancer
LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors .

HY-120402

BMS-200	PD-1/PD-L1	Inflammation/Immunology
BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 80 nM. BMS-200 can induce dimerization of PD-L1 .

HY-103692

STX-0119 2 Publications Verification	STAT	Cancer
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .

HY-153890

NVOC cage-TMP-Halo	Biochemical Assay Reagents	Others
NVOC cage-TMP-Halo is a cell-permeable and photoactivatable protein dimerization inducer. NVOC cage-TMP-Halo can rapidly and reversibly control protein localization in living cells. NVOC cage-TMP-Halo can be used for dynamic cellular processes research .

HY-12124

BBS-4	NO Synthase	Cardiovascular Disease
BBS-4 is a potent and selective inducible nitric oxide synthase (NOS2) dimerization inhibitor, with an IC₅₀ of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis .

HY-18061

Ochromycinone 3 Publications Verification (Rac)-STA-21	Antibiotic STAT Bacterial	Infection Cancer
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity .

HY-176749

HUP-46	α-synuclein Atg8/LC3 Autophagy	Neurological Disease
HUP-46 is a BBB-penatrable modulator of αSyn dimerization and autophagy. HUP-46 reduces the ratio of pPP2A/PP2A, increases the autophagy marker LC3BII levels, and decreases αSyn dimerization. HUP-46 can be used for research of neurodegenerative diseases .

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

HY-144121

Ph-Ph+	Bacterial Fungal Apoptosis	Infection Cancer
Ph-Ph+ is a hemiprotonic compound, which is produced from phenanthroline (ph) dimerization. Ph-Ph+ has antitumor, antibacterial and antifungal activities .

HY-100669

Mycro 3 5 Publications Verification	c-Myc Autophagy	Cancer
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .

HY-W008356

2-Fluoro-4-iodobenzonitrile	Drug Intermediate	Infection Metabolic Disease
2-Fluoro-4-iodobenzonitrile is a building block, which can be used to synthesize L. infantum trypanothione reductase (Li-TryR) dimerization and oxidoreductase activity inhibitors. 2-Fluoro-4-iodo benzonitrile can also be used to synthesize transient receptor potential ankyrin 1 (TRPA1) antagonists .

HY-18061R

Ochromycinone (Standard) (Rac)-STA-21 (Standard)	Antibiotic Reference Standards STAT Bacterial	Infection Cancer
Ochromycinone (Standard) ((Rac)-STA-21 (Standard)) is the analytical standard of Ochromycinone (HY-18061). This product is intended for research and analytical applications. Ochromycinone is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-124843

LLL3 CLT-005	STAT Apoptosis	Cancer
LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer .

HY-102011

BMS-1166 5 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-134269

8-Br-7-CH-cADPR 7-Deaza-8-bromo-cADPR; 7-Deaza-8-bromo-cyclic ADP ribose	Calcium Channel	Neurological Disease
8-Br-7-CH-cADPR (7-Deaza-8-bromo-cADPR) is a potent cADPR antagonist. 8-Br-7-CH-cADPR shows partial inhibition of calcium elevation caused by sTIR dimerization. 8-Br-7-CH-cADPR significantly decreases Paclitaxel (HY-B0015)-induced axon degeneration .

HY-111009

Swinholide A	Fungal	Infection
Swinholide A is the actin-binding marine polyketide and dimerizes actin with the K_d of ~ 50 nM . Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments. Swinholide A disrupts the actin cytoskeleton of cells.Antifungal activity .

HY-134269A

8-Br-7-CH-cADPR disodium 7-deaza-8-bromo-cADPR disodium; 7-deaza-8-bromo-cyclic ADP ribose disodium	Calcium Channel	Neurological Disease
8-Br-7-CH-cADPR disodium (7-Deaza-8-bromo-cADPR) is a potent cADPR antagonist. 8-Br-7-CH-cADPR disodium shows partial inhibition of calcium elevation caused by sTIR dimerization. 8-Br-7-CH-cADPR disodium significantly decreases Paclitaxel (HY-B0015)-induced axon degeneration .

HY-122678

LQZ-7F	Survivin Apoptosis	Cancer
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC₅₀s of 2.99 and 2.47 µM, respectively .

HY-126558

GA3-AM	Phytohormone	Others
GA3-AM is a cell permeable analog of the plant hormone gibberellic acid that acts as a chemical dimerizer or chemical inducer of dimerization .

HY-16046

Rimiducid 45+ Cited Publications AP1903	FKBP Apoptosis	Cancer
Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.

HY-N11101

Procyanidin A5'	Others	Others
Procyanidin A5' is A dimerized proanthocyanidin type A .

HY-18932

DEL-22379 2 Publications Verification	ERK Apoptosis	Cancer
DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a K_d estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC₅₀ of ~0.5 μM.

HY-124500

AC-4-130 5+ Cited Publications	STAT Apoptosis	Cancer
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .

HY-126558R

GA3-AM (Standard)	Phytohormone Reference Standards	Others
GA3-AM (Standard) is the analytical standard of GA3-AM. This product is intended for research and analytical applications. GA3-AM is a cell permeable analog of the plant hormone gibberellic acid that acts as a chemical dimerizer or chemical inducer of dimerization .

HY-P3833

Yp537 Anti-estrogen	Estrogen Receptor/ERR	Endocrinology
Yp537 is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

HY-P3833A

Yp537 TFA Anti-estrogen TFA	Estrogen Receptor/ERR	Endocrinology
Yp537 TFA is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

HY-100996

10074-G5 2 Publications Verification	c-Myc Autophagy	Cancer
10074-G5 is an inhibitor of c-Myc-Max dimerization with an IC₅₀ of 146 μM.

HY-P3223

Biphalin TFA	Opioid Receptor	Neurological Disease
Biphalin TFA, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores. Biphalin TFA has high affinity for opioid receptors. Biphalin TFA shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin TFA is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .

HY-150252

ATIC-IN-1	Others	Cancer
ATIC-IN-1(compound 14) is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a K_i value of 685 nM. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 exhibits anti-tumor activity via reduction in cell numbers and cell division rates .

HY-150252A

ATIC-IN-1 acetate 1 Publications Verification	Endogenous Metabolite	Cancer
ATIC-IN-1 (compound 14) acetate is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a K_i value of 685 nM, whcich catalyzes de novo purine biosynthesis. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 acetate exhibits anti-tumor activity via reduction in cell numbers and cell division rates .

HY-127041

Virstatin	Bacterial	Infection
Virstatin inhibits the pili system synthesis and prevents A. baumannii biofilm formation. Virstatin also inhibits dimerization of the transcriptional activator ToxT .

HY-P9912

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-12702

10058-F4 45+ Cited Publications	c-Myc Autophagy	Cancer
10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

HY-160783

SRI-43265	HuR	Cancer
SRI-43265 (compound 40) is an inhibitor of human antigen R protein (HuR) dimerization, and HuR multimers have been implicated in cancer and inflammatory pathogenesis .

HY-P9912A

Pertuzumab (anti-HER2)	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-E70704

EGFR G719C Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719C Recombinant Human Active Protein Kinase is a recombinant EGFR G719C protein that can be used to study EGFR G719C-related functions .

HY-E70706

EGFR L718Q Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L718Q Recombinant Human Active Protein Kinase is a recombinant EGFR L718Q protein that can be used to study EGFR L718Q-related functions .

HY-E70695

EGFR C797S Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR C797S Recombinant Human Active Protein Kinase is a recombinant EGFR C797S protein that can be used to study EGFR C797S-related functions .

HY-E70707

EGFR L858R Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L858R Recombinant Human Active Protein Kinase is a recombinant EGFR L858R protein that can be used to study EGFR L858R-related functions .

HY-E70708

EGFR L861Q Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L861Q Recombinant Human Active Protein Kinase is a recombinant EGFR L861Q protein that can be used to study EGFR L861Q-related functions .

HY-E70705

EGFR G719S Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719S Recombinant Human Active Protein Kinase is a recombinant EGFR G719S protein that can be used to study EGFR G719S-related functions .

HY-E70709

EGFR T790M Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M Recombinant Human Active Protein Kinase is a recombinant EEGFR T790M protein that can be used to study EGFR T790M-related functions .

HY-E70703

EGFR d752-759 Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d752-759 Recombinant Human Active Protein Kinase is a recombinant EGFR d752-759 protein that can be used to study EGFR d752-759-related functions .

HY-E70697

EGFR d746-750 Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750 Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750 protein that can be used to study EGFR d746-750-related functions .

HY-178201

JLJ648	HIV Pyroptosis	Infection
JLJ648 is a Gag-Pol dimerizer with antiviral activity. JLJ648 can inhibit HIV replication and induce infected cell pyroptosis. JLJ648 can be used for the research of infection, such as HIV (human immunodeficiency virus) .

HY-13992

AP20187 40+ Cited Publications B/B Homodimerizer	FKBP	Metabolic Disease
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

HY-P5321

bFGF (119-126) 4 Publications Verification	FGFR	Others
bFGF (119-126) is a biological active peptide. (This peptide corresponds to human, bovine (119-126), mouse, rat (118-125) and Heparin-Binding Growth Factor 2 (118-125) residues of bFGF. It inhibits dimerization and activation of bFGF receptors.)

HY-50937

ST 2825 Maximum Cited Publications 68 Publications Verification	MyD88	Inflammation/Immunology
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity .

Cat. No.	Product Name

HY-L906

Norepinephrine Transporter (NET) Compound Library

648 compounds

On May 15, 2024, "Dimerization and antidepressant recognition at noradrenaline transporter" was published online by Nature. The research findings were an effort from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This study unraveled the important neural system target - the noradrenaline transporter (NET), obtaining the binding modes of human NET homodimers with the natural substrate norepinephrine (NE) and six selective antidepressants. It laid an important theoretical foundation for understanding the physiological regulation mechanisms of NET and other monoamine transporters.

The Norepinephrine Transporter (NET) Compound Library is obtained by computer-aided virtual screening based on the HY-L901 compound library . The specific screening process includes molecular docking screening, key pharmacophore screening, and CNS-MPO screening, which can be used for new drug discovery targeting the noradrenaline transporter.

HY-L008

JAK/STAT Compound Library

613 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 613 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Type

HY-136277

DFHO	Fluorescent Dyes/Probes
DFHO is a fluorogenic ligand of Corn fluorogenic aptamer. The RNA aptamer, Corn binds DFHO with a K_d value of 70 nM and converts it to a fluorescent form, enabling RNA imaging in cells .

HY-100575

Acriflavine

5+ Cited Publications

Acriflavinium chloride 3,6-Acridinediamine mix

Fluorescent Dyes/Probes

Acriflavine (Acriflavinium chloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine is an antiseptic agent. Acriflavine is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2 .

HY-W154295

Purple-β-D-Gal	Fluorescent Dyes/Probes
Purple-β-D-Gal is a chromogenic β-galactosidase substrate. Intracellular enzymatic hydrolysis of Purple-β-D-Gal generates free indoxyl molecules, which undergo in situ oxidation and subsequent dimerization to produce chromogenic, water-insoluble, indigo precipitates. Purple-β-D-Gal can be used for the detection of β-galactosidase activity .

Cat. No.	Product Name	Target	Research Area

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-P5321

bFGF (119-126) 4 Publications Verification	FGFR	Others
bFGF (119-126) is a biological active peptide. (This peptide corresponds to human, bovine (119-126), mouse, rat (118-125) and Heparin-Binding Growth Factor 2 (118-125) residues of bFGF. It inhibits dimerization and activation of bFGF receptors.)

HY-P10426

cyclo(CLLFVY)	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC₅₀ of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

HY-P3833

Yp537 Anti-estrogen	Estrogen Receptor/ERR	Endocrinology
Yp537 is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

HY-P3833A

Yp537 TFA Anti-estrogen TFA	Estrogen Receptor/ERR	Endocrinology
Yp537 TFA is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

HY-P3223

Biphalin TFA	Opioid Receptor	Neurological Disease
Biphalin TFA, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores. Biphalin TFA has high affinity for opioid receptors. Biphalin TFA shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin TFA is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .

HY-P11072

IRF5-CPP5	Toll-like Receptor (TLR)	Inflammation/Immunology
IRF5-CPP5 is a cytosolic peptide that selectively inhibits human IRF5 with IC₅₀ values of 15.4 and 15.3 μM for recombinant S430D or wild-type (WT) IRF5 dimerization, respectively. .

HY-P10793

Cyclic(YCDGFYACYMDV)	EGFR Apoptosis	Cancer
Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

HY-P4121

L17E	Potassium Channel	Inflammation/Immunology Cancer
L17E is an attenuated cationic amphiphilic lytic (ACAL) peptide that can be used to deliver a variety of macromolecules, including proteins, antibodies, and DNA nanostructures. L17E inserts and cleaves the membrane structure through electrostatic interaction, enabling intracellular escape. The efficiency of L17E-mediated delivery is strongly correlated with the expression level of KCNN4 (the gene encoding the calcium-activated potassium channel KCa3.1). L17E also promotes the cellular uptake of macromolecules by inducing micropinocytosis. L17E can be further optimized and improved through dimerization strategies and in combination with other delivery systems, such as nuclear localization signal peptides and cell membrane-coated nanoparticles .

Cat. No.	Product Name	Target	Research Area

HY-P9912

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P9912A

Pertuzumab (anti-HER2)	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P991237

Nezutatug HMBD-001	EGFR	Cancer
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .

HY-P99391

Telisotuzumab ABT-700	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P99245

Emactuzumab RG 7155; RO 5509554	c-Fms	Cancer
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-P991240

CDX-3379	EGFR	Cancer
CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18061

Ochromycinone 3 Publications Verification (Rac)-STA-21	Infection Quinones Monophenols Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Disease Research Fields	Antibiotic STAT Bacterial
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity .

HY-111009

Swinholide A	Infection Natural Products Classification of Application Fields Animals Source classification Marine natural products Sponge Disease Research Fields	Fungal
Swinholide A is the actin-binding marine polyketide and dimerizes actin with the K_d of ~ 50 nM . Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments. Swinholide A disrupts the actin cytoskeleton of cells.Antifungal activity .

HY-18061R

Ochromycinone (Standard) (Rac)-STA-21 (Standard)	Quinones Monophenols Microorganisms Anthraquinones Source classification Phenols	Antibiotic Reference Standards STAT Bacterial
Ochromycinone (Standard) ((Rac)-STA-21 (Standard)) is the analytical standard of Ochromycinone (HY-18061). This product is intended for research and analytical applications. Ochromycinone is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.

HY-N11101

Procyanidin A5'	Prunus spinosa L. Source classification Rosaceae Phenols Polyphenols Plants	Others
Procyanidin A5' is A dimerized proanthocyanidin type A .

Cat. No.	Compare	Product Name	Species	Source

HY-P71203

	PHS Protein, Human (His) Pterin-4-Alpha-Carbinolamine Dehydratase; PHS; 4-Alpha-Hydroxy-Tetrahydropterin Dehydratase; dimerization Cofactor of Hepatocyte Nuclear Factor 1-Alpha; DCoH; dimerization Cofactor of HNF1; Phenylalanine Hydroxylase-Stimulating Protein; Pterin Carbinolamine Dehy	Human	E. coli
	PHS protein is crucial in tetrahydrobiopterin biosynthesis and has the dual function of hindering the formation of 7-pterin and promoting quinone-BH2. It also acts as a coactivator of HNF1A-dependent transcription, affecting HNF1A dimerization and enhancing its activity. PHS Protein, Human (His) is the recombinant human-derived PHS protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15148S1

Tipranavir-d7
Tipranavir-d₇ is deuterated labeled Tipranavir (HY-15148). Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC₅₀s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL ^pro activity .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83021

	DP1 Antibody (YA2766) TFDP1; DP1; Transcription factor Dp-1; DRTF1-polypeptide 1; DRTF1; E2F dimerization partner 1	WB, FC	Human, Mouse, Rat
	DP1 Antibody (YA2766) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DP1.

HY-P87379

	PCBD1 Antibody (YA7062) 4 alpha hydroxy tetrahydropterin dehydratase antibody; 4-alpha-hydroxy-tetrahydropterin dehydratase antibody; 6 pyruvoyl tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (TCF1) antibody; 6 pyruvoyl tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha antibody; DCoH antibody; dimerization cofactor of hepatic nuclear factor 1 alpha antibody; dimerization cofactor of hepatocyte nuclear factor 1 alpha antibody; dimerization cofactor of hepatocyte nuclear factor 1-alpha antibody; dimerization cofactor of HNF1 antibody; Dimerizing cofactor for HNF1 antibody	WB, IHC-P	Human, Mouse, Rat
	PCBD1 Antibody (YA7062) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PCBD1.

HY-P82484

	*Max Dimerization* Protein 3 Antibody (YA2229)** bHLHc13; mxd3; Myx	WB, IHC-P, FC	Human, Mouse, Rat
	Max Dimerization Protein 3 Antibody (YA2229) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Max Dimerization Protein 3.